He Adium Laboratory has officially announced the arrival of a molecule capable of activating two hormone receptors simultaneously, an innovation that strives to achieve this increase fat mass loss and the Metabolic control in patients with precise indications in healthcare settings, where obesity affects a large proportion of the adult population.
The medicine has the trade name Mounjaro. Its active ingredient, Tirzepatideis characterized by the fact that it mimics the role of two hormones that the body produces naturally. Activates the receptors of the GIP (glucose-dependent insulinotropic peptide) and GLP-1 (glucagon-like peptide-1), which releases signals in the intestine reduce food intakeincrease the feeling of satiety and increase insulin secretion. GIP acts as a modulator of adipose tissue metabolism.
Monica KatzCoordinator of the Obesity Group of the Argentine Nutrition Society (SAN), explained the advantage of this combination at the launch. “It creates a synergistic effect: while GLP-1 reduces appetite, improves satiety and promotes slower gastric emptying“GIP acts directly on the fatty tissue and leads to weight loss, predominantly at the expense of fat mass,” explained the specialist.
Clinical studies show a reduction from up to a 26% of body weight in 72 weeks Treatment with maximum doses. The Semaglutidethe injection preparation that precedes this technology, reaches up to 17%. Katz noted that these results are similar to those of bariatric surgeries without the need for surgery.
A mandatory doctor’s prescription is required to use Mounjaro. Experts recommend it as a supplement to diet and exercise Type 2 diabetes inadequately controlled. The National Drug, Food and Medical Device Administration (Anmat) also approves its use for chronic weight control in over 18 years old with obesity, defined by a body mass index (BMI) of at least 30.
Obese patients (BMI equal to or greater than 27) can access treatment if they have a corresponding health condition. These comorbidities include high blood pressure, high cholesterol, heart disease, prediabetes or sleep apnea. The World Health Organization (WHO) recommends its use under strict professional supervision.
Administration of the drug consists of a weekly subcutaneous injection Using a prefilled, multi-dose pen known as KwikPen. The product must be stored cool, between 2°C and 8°C. The medical system suggests: a Step treatment with the dosage increasing according to the patient’s response and ranging between 2.5 mg and 15 mg. The Adium laboratory, which is responsible for commercialization through an agreement with Eli Lilly, confirmed the current availability of the 2.5 mg and 5 mg versions. The largest concentrations will arrive next year.
The selling price reflects the complexity of the innovation. The Four monthly doses of Mounjaro 5 mg cost $783,858.40. The market offers other alternatives with different values. He wegovy (Novo Nordisk Semaglutide) Cost $717,827.21. The national option Obetide (Elea Lab) Okay $234,935.50 in its maximum dose.
Javier WaistblatDirector of AdiumHe pointed out these differences: “The comparison with other products doesn’t seem fair to us because.” Mounjaro has a dual mechanism of action“The executive anticipated a benefit system with discounts of up to 30% and pointed to the interest of healthcare providers in covering high-risk patients to avoid operations.”
Epigraph: Experts emphasize that the drug not only reduces weight, but also improves key indicators such as blood pressure and reduces the risk of heart failure
The Washington Post – The Washington PostThe benefit of the drug exceeds the numerical decrease on the scale. Jorge Tartaglioneformer president of the Argentine Cardiological Foundation (FCA) highlighted the direct link between obesity and cardiovascular risk. “Work on this dual action drug shows not only weight loss, but also a decrease in waist circumference, fatty liver, blood pressure, Heart failure“, explained the cardiologist, explaining that GIP and GLP-1 help the pancreas “Absorb energy”.
The presentation included testimony from Shiry AttieIntensive care physician at Cemic and participant in the clinical study. Attie then talked about his experiences Lose more than 30 kilos in 18 months. “All my life I’ve had weight problems, I’ve lost weight and gained it back, and I always felt that the problem wasn’t just a lack of will,” he confessed. Commenting on the effect of the treatment, he said: “Since I started using these injections, food is no longer a constant thought in my life. And my overall health has improved physically and mentally.”
This content was created by a LA NACION team with the support of AI from a Article signed by Gabriela Navarra Camerucci.
About The Author
